切换至 "中华医学电子期刊资源库"
高级检索
中华细胞与干细胞杂志(电子版)

中华细胞与干细胞杂志(电子版) ›› 2024, Vol. 14 ›› Issue (02) : 107 -112. doi: 10.3877/cma.j.issn.2095-1221.2024.02.006

综述

间充质干细胞及其衍生物治疗高原低氧环境下心血管疾病的研究进展
梁国豪1, 张茜2,†(), 张研1   
  1. 1. 730000　兰州，甘肃中医药大学第一临床医学院；730050　兰州，中国人民解放军联勤保障部队第九四〇医院血液科
    2. 730050　兰州，中国人民解放军联勤保障部队第九四〇医院血液科
  • 收稿日期:2024-01-21 出版日期:2024-04-01
  • 通信作者: 张茜
  • 基金资助:
    甘肃省卫生健康行业科研计划项目(GSWSKY 2021-044); 甘肃省科技计划项目(21JR1RA183); 西北民族大学中央高校基本科研业务费项目(31920220110); 中国人民解放军联勤保障部队第九四〇医院院内基金(2021yxky042)

Advance in mesenchymal stem cells for the treatment of cardiovascular diseases in the low- oxygen environment of plateau

Guohao Liang1, Qian Zhang2,†(), Yan Zhang1   

  1. 1. The First Clinical Medical College of Gansu University of Chinese Medicine, Lanzhou 730000 China; Department of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou 730050, China
    2. Department of Hematology, the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army, Lanzhou 730050, China
  • Received:2024-01-21 Published:2024-04-01
  • Corresponding author: Qian Zhang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

梁国豪, 张茜, 张研. 间充质干细胞及其衍生物治疗高原低氧环境下心血管疾病的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(02): 107-112.

Guohao Liang, Qian Zhang, Yan Zhang. Advance in mesenchymal stem cells for the treatment of cardiovascular diseases in the low- oxygen environment of plateau[J/OL]. Chinese Journal of Cell and Stem Cell(Electronic Edition), 2024, 14(02): 107-112.

心血管系统疾病死亡率位居各大系统首位。高原环境以缺氧为主要特征，就心脏而言，为适应低氧变化，可引发心肌细胞损伤、心室重塑和心功能低下等一系列问题，甚至可诱发或加重心血管疾病。间充质干细胞（MSCs）作为细胞疗法的主要参与者，通过直接再生、旁分泌作用、免疫调节、微环境改善和促进内源性心脏修复的方式应用于心血管系统，对高原低氧环境下心血管疾病具有疗效。近年来有关高原地区应用MSCs防治高原病的研究报道日益增多。现就MSCs在高原低氧环境下对心血管系统的影响作一阐述，旨在明确高原低氧环境下心血管系统的变化特点及MSCs对其作用机制和防治效果。

关键词: 高原, 低氧, 心血管系统, 间充质干细胞, 外泌体, HIF-1α

The mortality rate of cardiovascular diseases is the highest among all major systems. The plateau environment is mainly characterized by hypoxia, and in the case of the heart, adapting to the hypoxic changes triggers a series of problems such as cardiomyocyte damage, ventricular remodelling, and cardiac hypoplasia. It may even induce or aggravate cardiovascular diseases. Mesenchymal stem cells (MSCs) are a novel therapeutic strategy for cell therapy. They are applied to the cardiovascular system through direct regeneration, paracrine effects, immunomodulation, microenvironmental improvement, and promotion of endogenous cardiac repair. They are highly effective in cardiovascular diseases in the low-oxygen environment of a plateau. In recent years, there have been increasing research reports on applying MSCs to prevent and treat plateau diseases in plateau areas. Now, we would like to elaborate on the effects of MSCs on the cardiovascular system in a plateau hypoxia environment, aiming to clarify the characteristics of changes in the cardiovascular system in a plateau hypoxia environment, and the mechanism and preventive and therapeutic effect of MSCs.

Key words: Highland, Hypoxia, Cardiovascular system, Mesenchymal stem cells, Exosome, HIF-1α
图1 MSCs细胞疗法在心脏方面的主要调控方式注：MSCs为间充质干细胞；VEGF为血管内皮生长因子；HGF为肝细胞生长因子；IGF-1为胰岛素样生长因子1；SDF1为基质细胞衍生因子；TGF-β为转化生长因子-β；TSG-6为肿瘤坏死因子α刺激基因6；STAT3为信号转导及转录激活因子3；IL-10为白细胞介素-10
1
赵彩莲, 汪晓洲, 严萍. 高原病患者血压水平流行病学特征及其与糖代谢相关性分析[J]. 公共卫生与预防医学, 2022, 33(4):92-95.
2
张建起, 石蕊, 张芯, 等. 高原环境对心血管系统的影响及其防治措施[J]. 武警医学, 2022, 33(9):812-817.
3
Sriramulu S, Banerjee A, Jothimani G, et al. Conditioned medium from the human umbilical cord-mesenchymal stem cells stimulate the proliferation of human keratinocytes[J]. J Basic Clin Physiol Pharmacol, 2020, 32(2):51-56.
4
Wang Y, Shen Y. Exosomal miR-455-3p from BMMSCs prevents cardiac ischemia-reperfusion injury[J]. Hum Exp Toxicol, 2022, 41:774846548. doi: 10.1177/09603271221102508.
5
Xu Y, Fan P, Liu L, et al. Novel perspective in transplantation therapy of mesenchymal stem cells: targeting the ferroptosis pathway[J]. J Zhejiang Univ Sci B, 2023, 24(2):115-129.
6
李华,李晓帆,李乃农. 间充质干细胞促进脐带血干细胞体外扩增的研究进展 [J]. 中华细胞与干细胞杂志(电子版), 2022, 12 (1): 34-38.
7
Tremblay JC, Ainslie PN. Global and country-level estimates of human population at high altitude[J]. Proc Natl Acad Sci U S A, 2021, 118(18):e2102463118. doi:10.1073/pnas.2102463118.
8
Berger MM, Luks AM. High altitude[J]. Semin Respir Crit Care Med, 2023, 44(5):681-695.
9
张秋梅. 高原低氧对机体整体的影响及适应性分析[J]. 中外医疗, 2018, 37(11):187-189.
10
毛燕, 陶磊, 庞君, 等. 低压低氧对氧化-抗氧化系统的影响[J]. 现代生物医学进展, 2015, 15(15):2981-2984.
11
Richalet JP, Hermand E, Lhuissier FJ. Cardiovascular physiology and pathophysiology at high altitude[J]. Nat Rev Cardiol, 2024, 21(2):75-88.
12
Faeh D, Gutzwiller F, Bopp M. Lower mortality from coronary heart disease and stroke at higher altitudes in Switzerland[J]. Circulation, 2009, 120(6):495-501.
13
Winkelmayer WC, Hurley MP, Liu J, et al. Altitude and the risk of cardiovascular events in incident US dialysis patients[J]. Nephrol Dial Transplant, 2012, 27(6):2411-2417.
14
Jiang M, Fan X, Wang Y, et al. Effects of hypoxia in cardiac metabolic remodeling and heart failure[J]. Exp Cell Res, 2023, 432(1):113763. doi: 10.1016/j.yexcr.2023.113763.
15
Zheng J, Chen P, Zhong J, et al. HIF-1α in myocardial ischemia-reperfusion injury (Review)[J]. Mol Med Rep, 2021, 23(5):352. doi: 10.3892/mmr.2021.11991.
16
Semenza GL. Regulation of metabolism by hypoxia-inducible factor 1[J]. Cold Spring Harb Symp Quant Biol, 2011, 76:347-353.
17
Li X, Zhang Q, Nasser MI, et al. Oxygen homeostasis and cardiovascular disease:a role for HIF?[J]. Biomed Pharmacother, 2020, 128:110338. doi: 10.1016/j.biopha.2020.110338.
18
Semenza GL. Hypoxia-inducible factor 1 and cardiovascular disease[J]. Annu Rev Physiol, 2014, 76:39-56.
19
Cornolo J, Mollard P, Brugniaux JV, et al. Autonomic control of the cardiovascular system during acclimatization to high altitude:effects of sildenafil[J]. J Appl Physiol (1985), 2004, 97(3):935-940.
20
Vogel JA, Harris CW. Cardiopulmonary responses of resting man during early exposure to high altitude[J]. J Appl Physiol, 1967, 22(6):1124-1128.
21
Han CF, Li ZY, Li TH. Roles of hypoxia-inducible factor-1α and its target genes in neonatal hypoxic pulmonary hypertension[J]. Eur Rev Med Pharmacol Sci, 2017, 21(18):4167-4180.
22
Mingji C, Onakpoya IJ, Perera R, et al. Relationship between altitude and the prevalence of hypertension in tibet: a systematic review[J]. Heart, 2015, 101(13):1054-1060.
23
陈颖, 刘洋, 王晓宇. 原发性高血压患者血清periostin、ET-1、VEGF水平变化及临床意义[J]. 中国循证心血管医学杂志, 2019, 11(4):455-457.
24
Luks AM, Hackett PH. Medical conditions and high-altitude travel[J]. N Engl J Med, 2022, 386(4):364-373.
25
Parati G, Agostoni P, Basnyat B, et al. Clinical recommendations for high altitude exposure of individuals with pre-existing cardiovascular conditions: a joint statement by the European Society of Cardiology, the Council on Hypertension of the European Society of Cardiology, the European Society of Hypertension, the International Society of Mountain Medicine, the Italian Society of Hypertension and the Italian Society of Mountain Medicine[J]. Eur Heart J, 2018, 39(17):1546-1554.
26
Richalet JP, Hermand E, Lhuissier FJ. Cardiovascular physiology and pathophysiology at high altitude[J]. Nat Rev Cardiol, 2024, 21(2):75-88.
27
王佃亮, 李燕妮. 间充质干细胞移植治疗作用机制[J]. 转化医学杂志, 2019, 8(5):257-261.
28
Naji A, Eitoku M, Favier B, et al. Biological functions of mesenchymal stem cells and clinical implications[J]. Cell Mol Life Sci, 2019, 76(17):3323-3348.
29
Eliasson P, Jönsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be[J]. J Cell Physiol, 2010, 222(1):17-22.
30
张研, 雷胜男, 张茜, 等. 间充质干细胞及外泌体对高原脑水肿的潜在作用机制研究进展[J]. 实用临床医药杂志, 2024, 28(2):129-134.
31
Liu L, Jin X, Hu CF, et al. Exosomes derived from mesenchymal stem cells rescue myocardial ischaemia/reperfusion injury by inducing cardiomyocyte autophagy via AMPK and Akt pathways[J]. Cell Physiol Biochem, 2017, 43(1):52-68.
32
Xu W, Xu R, Li Z, et al. Hypoxia changes chemotaxis behaviour of mesenchymal stem cells via HIF-1α signalling[J]. J Cell Mol Med, 2019, 23(3):1899-1907.
33
Pulido-Escribano V, Torrecillas-Baena B, Camacho-Cardenosa M, et al. Role of hypoxia preconditioning in therapeutic potential of mesenchymal stem-cell-derived extracellular vesicles[J]. World J Stem Cells, 2022, 14(7):453-472.
34
Tang Y, Zhou Y, Li HJ. Advances in mesenchymal stem cell exosomes: a review[J]. Stem Cell Res Ther, 2021, 12(1):71. doi: 10.1186/s13287-021-02138-7.
35
Sun J, Shen H, Shao L, et al. HIF-1α overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis[J]. Stem Cell Res Ther, 2020, 11(1):373. doi: 10.1186/s13287-020-01881-7.
36
Sun XH, Wang X, Zhang Y, et al. Exosomes of bone-marrow stromal cells inhibit cardiomyocyte apoptosis under ischemic and hypoxic conditions via miR-486-5p targeting the PTEN/PI3K/AKT signaling pathway[J]. Thromb Res, 2019, 177:23-32.
37
Wen Z, Mai Z, Zhu X, et al. Mesenchymal stem cell-derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway[J]. Stem Cell Res Ther, 2020, 11(1):36. doi: 10.1186/s13287-020-1563-8.
38
Zhang S, Liu X, Ge LL, et al. Mesenchymal stromal cell-derived exosomes improve pulmonary hypertension through inhibition of pulmonary vascular remodeling[J]. Respir Res, 2020, 21(1):71. doi: 10.1186/s12931-020-1331-4.
39
Sun W, Lv J, Guo S, et al. Cellular microenvironment: a key for tuning mesenchymal stem cell senescence[J]. Front Cell Dev Biol, 2023, 11:1323678. doi: 10.3389/fcell.2023.1323678.
40
Ni X, Ou C, Guo J, et al. Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro[J]. Int J Mol Med, 2017, 40(2):418-426.
41
Müller P, Lemcke H, David R. Stem cell therapy in heart diseases-cell types, mechanisms and improvement strategies[J]. Cell Physiol Biochem, 2018, 48(6):2607-2655.
42
Song H, Song BW, Cha MJ, et al. Modification of mesenchymal stem cells for cardiac regeneration[J]. Expert Opin Biol Ther, 2010, 10(3):309-319.
43
Tsiapalis D, O'Driscoll L. Mesenchymal stem cell derived extracellular vesicles for tissue engineering and regenerative medicine applications[J]. Cells, 2020, 9(4):991.doi: 10.3390/cells9040991.
44
Pan Y, Wu W, Jiang X, et al. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases:from mechanisms to therapy[J]. Biomed Pharmacother, 2023, 163:114817. doi: 10.1016/j.biopha.2023.114817.
45
Sun SJ, Wei R, Li F, et al. Mesenchymal stromal cell-derived exosomes in cardiac regeneration and repair[J]. Stem Cell Reports, 2021, 16(7):1662-1673.
46
Sid-Otmane C, Perrault LP, Ly HQ. Mesenchymal stem cell mediates cardiac repair through autocrine,paracrine and endocrine axes[J]. J Transl Med, 2020, 18(1):336. doi: 10.1186/s12967-020-02504-8.
47
Liu Y, Chen J, Liang H, et al. Human umbilical cord-derived mesenchymal stem cells not only ameliorate blood glucose but also protect vascular endothelium from diabetic damage through a paracrine mechanism mediated by MAPK/ERK signaling[J]. Stem Cell Res Ther, 2022, 13(1):258.
48
Constantinou C, Miranda A, Chaves P, et al. Human pluripotent stem cell-derived cardiomyocytes as a target platform for paracrine protection by cardiac mesenchymal stromal cells[J]. Sci Rep, 2020, 10(1):13016. doi: 10.1038/s41598-020-69495-w.
49
McQuaig R, Dixit P, Yamauchi A, et al. Combination of cardiac progenitor cells from the right atrium and left ventricle exhibits synergistic paracrine effects in vitro[J]. Cell Transplant, 2020, 29:2138965032. doi: 10.1177/0963689720972328.
50
余怡. 人胎肝间充质干细胞与成人骨髓间充质干细胞的免疫调节功能的比较研究[D]. 北京:北京协和医学院, 2021.
51
Wang Y, Qi Z, Yan Z, et al. Mesenchymal stem cell immunomodulation: a novel intervention mechanism in cardiovascular disease[J]. Front Cell Dev Biol, 2021, 9:742088.doi: 10.3389/fcell.2021.742088.
52
Liu J, Gao J, Liang Z, et al. Mesenchymal stem cells and their microenvironment[J]. Stem Cell Res Ther, 2022, 13(1):429. doi: 10.1186/s13287-022-02985-y.
53
Jiang F, Zhang W, Zhou M, et al. Human amniotic mesenchymal stromal cells promote bone regeneration via activating endogenous regeneration[J]. Theranostics, 2020, 10(14):6216-6230.
54
Jia N, Shen Z, Zhao S, et al. Eleutheroside E from pre- treatment of acanthopanax senticosus (Rupr.etMaxim.) harms ameliorates high-altitude-induced heart injury by regulating NLRP3 inflammasome-mediated pyroptosis via NLRP3/caspase-1 pathway[J]. Int Immunopharmacol, 2023, 121:110423. doi: 10.1016/j.intimp.2023.110423.
55
牛佳慧, 李琳, 沈国双, 等. 高原性心脏病的研究进展[J]. 高原医学杂志, 2018, 28(3):59-64.
56
Ge RL, Helun G. Current concept of chronic mountain sickness: pulmonary hypertension-related high-altitude heart disease[J]. Wilderness Environ Med, 2001, 12(3):190-194.
57
Luna-López R, Ruiz MA, Escribano SP. Pulmonary arterial hypertension[J]. Med Clin(Barc), 2022, 158(12):622-629.
58
Sun QW, Sun Z. Stem cell therapy for pulmonary arterial hypertension: an update[J]. J Heart Lung Transplant, 2022, 41(6):692-703.
59
刘鑫源, 陈兴书, 罗勇军. 波生坦防治高原肺动脉高压相关疾病研究进展[J]. 人民军医, 2020, 63(1):79-83.
60
刘方洲, 李高元, 李相俊, 等. 高原地区青年急性心肌梗死1例报道[J]. 临床合理用药杂志, 2022, 15(12):175-178.
61
薛峰. 高海拔地区对心肌梗死患者预后影响1例分析[J]. 名医, 2020, (8):46-47.
62
Wang X, Tang Y, Liu Z, et al. The application potential and advance of mesenchymal stem cell-derived exosomes in myocardial infarction[J]. Stem Cells Int, 2021, 2021:5579904. doi: 10.1155/2021/5579904.
[1] 刘政宏, 袁春銮. 乳腺癌患者血清外泌体中长链非编码RNA BC200的表达及临床意义[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(04): 212-216.
[2] 林琳, 田思萌, 于永华, 徐飞飞, 黄明莉. 干细胞及其外泌体治疗宫腔黏连的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 271-275.
[3] 刘昌玲, 张金丽, 张志, 李孝建, 汤文彬, 胡逸萍, 陈宾, 谢晓娜. 负载人脂肪干细胞外泌体的甲基丙烯酰化明胶水凝胶对人皮肤成纤维细胞增殖和迁移的影响[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 517-525.
[4] 宋勤琴, 李双汝, 李林, 杜鹃, 刘继松. 间充质干细胞源性外泌体在改善病理性瘢痕中作用的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 550-553.
[5] 曹胜军, 李全, 符雪, 邵天喜, 周延华. 人脂肪间充质干细胞多层膜片对促进裸鼠皮肤缺损愈合的效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(04): 341-347.
[6] 张敏龙, 杨翠平, 王博, 崔云杰, 金发光. MiR-200b-3p 通过抑制HIF-1α 表达减轻海水吸入诱导的肺水肿作用及机制[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 696-700.
[7] 蔡定钦, 孙建国, 陈旭. 外泌体非编码RNAs与肺癌放射治疗的研究进展[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 655-658.
[8] 傅红兴, 王植楷, 谢贵林, 蔡娟娟, 杨威, 严盛. 间充质干细胞促进胰岛移植效果的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 351-360.
[9] 王大伟, 陆雅斐, 皇甫少华, 陈玉婷, 陈澳, 江滨. 间充质干细胞通过调控免疫机制促进创面愈合的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 361-366.
[10] 袁园园, 岳乐淇, 张华兴, 武艳, 李全海. 间充质干细胞在呼吸系统疾病模型中肺组织分布及治疗机制的研究进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 374-381.
[11] 王俊楠, 刘晔, 李若涵, 叶青松. 间充质干细胞调控肠脑轴治疗神经系统疾病的潜力[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 313-319.
[12] 袁雨涵, 杨盛力. 体液和组织蛋白质组学分析在肝癌早期分子诊断中的研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 883-888.
[13] 仝心语, 谭凯, 白亮亮, 杜锡林. 外泌体在肝细胞癌诊疗中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(03): 384-388.
[14] 季鹏程, 鄂一民, 陆晨, 喻春钊. 循环外泌体相关生物标志物在结直肠癌诊断中的研究进展[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(04): 265-273.
[15] 汪鹏飞, 程莹莹, 赵海康. 骨髓间充质干细胞改善神经病理性疼痛的机制探讨[J/OL]. 中华脑科疾病与康复杂志(电子版), 2024, 14(04): 230-234.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号

AI
小
编
AI小编
你好！我是《中华医学电子期刊资源库》AI小编，有什么可以帮您的吗？